Ketogenic Diet, Pain and Inflammation:
Множественные гипотезы лежат в основе теоретически обоснованных гипоаллергических и противовоспалительных эффектов кетогенной диеты. Здесь мы выделим четыре основных теоретически обоснованных механизма:
- Как и приступы эпилепсии, хроническая боль, как полагают, связана с повышенной возбудимостью нейронов; для боли это может включать периферические и / или центральные нейроны. 6, 7 Таким образом, есть некоторые сходство базовой биологии.
- Противосудорожные препараты часто назначают для невропатической боли, которая плохо реагирует на типичные обезболивающие препараты (см. ниже). Логически, из этого можно сделать вывод, что если есть общности в действиях противосудорожных препаратов и кетогенной диеты, последняя должна иметь некоторое влияние и на нейропатические боли.
- Снижение гликолитического метаболизма, по-видимому, является противосудорожным, независимо от того, достигается ли голодом, ограничением калорийности, высоким содержанием жира и ограничением углеводов (кетогенная диета, модифицированная диета Аткинса), 4, 5 или специфически блокирующий гликолиз с 2-дезоксиглюкозой. 8 Параллельно голодание и 2-деоксиглюкоза являются одновременно анальгетиками, 9, 10, поэтому кетогенная диета также может иметь обезболивающий эффект.
- Нейромодулятор аденозин может быть обезболивающим 11, 12 и участвует в эффектах акупунктуры, 13, 14 идет накопление фактов, что метаболические изменения в результате таких режимов таких как голодание, кетогенная диета и присутствие 2-дезоксиглюкозы, усиливают сигнализацию аденозина. 15, 16, 17, 18, 19 Недавние данные свидетельствуют о том, что физические упражнения могут лечить невропатические боли через механизм, в основании которого задействован аденозин. 20
Несмотря на эти дублирования и клинический потенциал, мало изучалась прямая взаимосвязь между кетогенными диетами и болью. Недавно боль была особо выделена в обзоре неврологических расстройств, которые следует учитывать при метаболической терапии 21 ; Очевидно, что лечение боли и воспаления является распространенной и неудовлетворенной потребностью. Здесь мы представляем доказательства клинических и фундаментальных исследований, включая положительные и отрицательные результаты наших лаборатория, идентифицирующия кетогенные диеты как платформу, заслуживающую дальнейшей оптимизации и исследования.
Ссылки:
- Elliott AM, Smith BH, Penny KI, et al. The epidemiology of chronic pain in the community. Lancet. 1999; 354:1248–1252. [PubMed: 10520633]
- Becker N, Bondegaard-Thomsen A, Olsen AK, et al. Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. Pain. 1997; 73:393–400. [PubMed: 9469530]
- Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization study in primary care. J Am Med Assoc. 1998; 280:147–151.
- Wilder RM. The effects of ketonemia on the course of epilepsy. Mayo Clin Bull. 1921; 2:307.
- Wilder RM. High fat diets in epilepsy. Mayo Clin Bull. 1921; 2:308.
- Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature. 1983; 306:686–688. [PubMed: 6656869]
- Raja SN, Meyer RA, Campbell JN. Peripheral mechanisms of somatic pain. Anesthesiology. 1988; 68:571–590. [PubMed: 3281512]
- Stafstrom CE, Ockuly JC, Murphree L, et al. Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models. Ann Neurol. 2009; 65:435–447. [PubMed: 19399874]
- Fisher MC, Bodnar RJ. 2-Deoxy-D-glucose antinociception and serotonin receptor subtype antagonists: test-specific effects in rats. Pharmacol Biochem Behav. 1992; 43:1241–1246. [PubMed: 1475308]
- delosSantos-Arteaga M, Sierra-Domínguez SA, Fontanella GH, et al. Analgesia induced by dietary restriction is mediated by the κ-opioid system. J Neurosci. 2003; 23:11120–11126. [PubMed: 14657170]
- Yarbrough GG, McGuffin-Clineschmidt JC. In vivo behavioral assessment of central nervous system purinergic receptors. Eur J Pharmacol. 1981; 76:137–144. [PubMed: 6895875]
- Schmidt AP, Böhmer AE, Antunes C, et al. Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br J Pharmacol. 2009; 156:163–172. [PubMed: 19133997]13. Goldman N, Chen M, Fujita T, et al. Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci. Jul.2010 13:883–888. [PubMed: 20512135]
- Goldman N, Chen M, Fujita T, et al. Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci. Jul.2010 13:883–888. [PubMed: 20512135]
- Takano T, Chen X, Luo F, et al. Traditional acupuncture triggers a local increase in adenosine in human subjects. J Pain. 2012; 13:1215–1223. [PubMed: 23182227]
- Zhao YT, Tekkök S, Krnjević K. 2-Deoxy-D-glucose-induced changes in membrane potential, input resistance, and excitatory postsynaptic potentials of CA1 hippocampal neurons. Can J Physiol Pharmacol. 1997; 75:368–374. [PubMed: 9250370]
- Minor TR, Rowe MK, Soames-Job RF, Ferguson EC. Escape deficits induced by inescapable shock and metabolic stress are reversed by adenosine receptor antagonists. Behav Brain Res. 2001; 120:203–212. [PubMed: 11182168]
- Kawamura M Jr, Ruskin DN, Masino SA. Metabolic autocrine regulation of neurons involves cooperation among pannexin hemichannels, adenosine receptors and KATP channels. J Neurosci. 2010; 30:3886–3895. [PubMed: 20237259]
- Jinka TR, Carlson ZA, Moore JT, Drew KL. Altered thermoregulation via sensitization of A1 adenosine receptors in dietary-restricted rats. Psychopharmacology. 2010; 209:217–224. [PubMed: 20186398]
- Masino SA, Li T, Theofilas P, et al. A ketogenic diet suppresses seizures in mice through adenosine A1 receptors. J Clin Invest. 2011; 121:2679–2683. [PubMed: 21701065]
- Martins DF, Mazzardo-Martins L, Soldi F, et al. High-intensity swimming exercise reduces neuropathic pain in an animal model of complex regional pain syndrome type I: evidence for a role of the adenosinergic system. Neuroscience. 2013; 234:69–76. [PubMed: 23291454]
- Ruskin DN, Masino SA. The nervous system and metabolic dysregulation: emerging evidence converges on ketogenic diet therapy. Front Neurosci. 2012; 6:33. [PubMed: 22470316]
- Ruskin DN, Kawamura M Jr, Masino SA. Reduced pain and inflammation in juvenile and adult rats fed a ketogenic diet. PLoS One. 2009; 4:e8349. [PubMed: 20041135]
23. Ruskin DN, Suter TACS, Ross JL, Masino SA. Ketogenic diets and thermal pain: dissociation of hypoalgesia, elevated ketones, and lowered glucose in rats. J Pain. 2013 in press. 10.1016/j.jpain. 2012.12.015 - Ruskin DN, Ross JL, Kawamura M Jr, et al. A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6/2 1J mouse model of Huntington’s disease. Physiol Behav. 2011; 103:501–507. [PubMed: 21501628]
- Ruskin DN, Ross JL, Kawamura M Jr, et al. A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6/2 1J mouse model of Huntington’s disease. Physiol Behav. 2011; 103:501–507. [PubMed: 21501628]
- Ziegler DR, Gamaro GD, Araújo E, et al. Nociception and locomotor activity are increased in ketogenic diet fed rats. Physiol Behav. 2005; 84:421–427. [PubMed: 15763579]
- Likhodii SS, Musa K, Mendonca A, et al. Dietary fat, ketosis, and seizure resistance in rats on the ketogenic diet. Epilepsia. 2000; 41:1400–1410. [PubMed: 11077453]
- Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids. 2004; 70:309–319. [PubMed: 14769489]
- Kim DY, Davis LM, Sullivan PG, et al. Ketone bodies are protective against oxidative stress in neocortical neurons. J Neurochem. 2007; 101:1316–1326. [PubMed: 17403035]
- Kim DY, Vallejo J, Rho JM. Ketones prevent synaptic dysfunction induced by mitochondrial respiratory complex inhibitors. J Neurochem. 2010; 114:130–141. [PubMed: 20374433]
- Noh HS, Hah YS, Nilufar R, et al. Acetoacetate protects neuronal cells from oxidative glutamate toxicity. J Neurosci Res. 2006; 83:702–709. [PubMed: 16435389]
31. - Maalouf M, Rho JM. Oxidative impairment of hippocampal long-term potentiation involves activation of protein phosphatase 2A and is prevented by ketone bodies. J Neurosci Res. 2008; 86:3322–3330. [PubMed: 18646208]
- Maalouf M, Sullivan PG, Davis L, et al. Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience. 2007; 145:256–264. [PubMed: 17240074]
- Haces ML, Hernandez-Fonseca K, Medina-Campos ON, et al. Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions. Exp Neurol. 2008; 211:85–96. [PubMed: 18339375]
- Sullivan PG, Rippy NA, Dorenbos K, et al. The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann Neurol. 2004; 55:576–580. [PubMed: 15048898]
- Kim DY, Hao J, Liu R, et al. Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. PLoS One. 2012; 7:e35476. [PubMed: 22567104]
- Tendler D, Lin S, Yancy WS Jr, et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007; 52:589–593. [PubMed: 17219068]
- Pérez-Guisado J, Muñoz-Serrano A. The effect of the Spanish Ketogenic Mediterranean Diet on nonalcoholic fatty liver disease: a pilot study. J Med Food. 2011; 14:677–680. [PubMed: 21688989]
- Schugar RC, Crawford PA. Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012; 15:374–380. [PubMed: 22617564]
- Michalik L, Auwerx J, Berger JP, et al. International Union of Pharmacology. LXI. Perixosome proliferator-activated receptors. Pharmacol Rev. 2006; 58:726–741. [PubMed: 17132851]
- Cuzzocrea S, Pisano B, Dugo L, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol. 2004; 483:79–93.[PubMed: 14709329]
- 41. Cuzzocrea S, Mazzon E, Dugo L, et al. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activatedreceptor gamma. Arthritis Rheum. 2003; 48:3544–3556. [PubMed: 14674008]
- LoVerme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67:15–19. [PubMed: 15465922]
- Cuzzocrea S, Mazzon E, Di Paolo R, et al. The role of the peroxisome proliferator-activated receptor-α (PPAR- α) in the regulation of acute inflammation. J Leukoc Biol. 2006; 79:999–1010. [PubMed: 16501055]
- Blanquart C, Barbier O, Fruchart JC, et al. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol. 2003; 85:267–273. [PubMed: 12943712]
- Kowaluk EA, Jarvis MF. Therapeutic potential of adenosine kinase inhibitors. Expert Opin Investig Drugs. 2000; 9:551–564.
- Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Ann Rev Pharmacol Toxicol. 2001; 41:775–787. [PubMed: 11264476]
- Ngamsri KC, Wagner R, Vollmer I, et al. Adenosine receptor A1 regulates polymorphonuclear cell trafficking and microvascular permeability in lipopolysaccharide-induced lung injury. J Immunol. 2010; 185:4374–4384. [PubMed: 20729330]
- Wang J, Huxley VH. Adenosine A2A receptor modulation of juvenile female rat skeletal muscle microvessel permeability. Am J Physiol Heart Circ Physiol. 2006; 291:H3094–H3105. [PubMed:16815983]
- Sorkin LS, Moore J, Boyle DL, et al. Regulation of peripheral inflammation by spinal adenosine:role of somatic afferent fibers. Exp Neurol. 2003; 184:162–168. [PubMed: 14637089]
- Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006; 52:77–92. [PubMed: 17015228]
- Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain. 1990; 43:273–286. [PubMed: 1705692]
- Dickenson AH, Suzuki R. Opioids in neuropathic pain: clues from animal studies. Eur J Pain. 2005; 9:113–116. [PubMed: 15737797]
- Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988; 33:87–107. [PubMed: 2837713]
- Uhlemann ER, Neims AH. Anticonvulsant properties of the ketogenic diet in mice. J Pharmacol Exp Ther. 1972; 180:231–238. [PubMed: 5010672]
- Samala R, Willis S, Borges K. Anticonvulsant profile of a balanced ketogenic diet in acute mouse seizure models. Epilepsy Res. 2008; 81:119–127. [PubMed: 18565731]
- Hartman AL, Zheng X, Bergbower E, et al. Seizure tests distinguish intermittent fasting from the ketogenic diet. Epilepsia. 2010; 51:1395–1402. [PubMed: 20477852]
- Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 2013; 110:3507–3512. [PubMed: 23401516]
- Rho, JM.; Zupec-Kania, B.; Masino, SA. Ketogenic diet and epilepsy: the role of adenosine. In: Masino, SA.; Boison, D., editors. Adenosine: A Key Link between Metabolism and Brain Activity. New York: Springer; 2013.
- Phillips CJ. Economic burden of chronic pain. Expert Rev Pharmacoecon Outcomes Res. 2006; 6:591–601. [PubMed: 20528505]
- Morrison PF, Pyzik PL, Hamdy R, et al. The influence of concurrent anticonvulsants on the efficacy of the ketogenic diet. Epilepsia. 2009; 50:1999–2001. [PubMed: 19389152]
- Poplawski MM, Mastaitis JW, Isoda F, et al. Reversal of diabetic nephropathy by a ketogenic diet. PLoS One. 2011; 6:e18604. [PubMed: 21533091]
- Atladottir HO, Thorsen P, Schendel DE, et al. Association of hospitalization for infection in childhood with diagnosis of autism spectrum disorders: a Danish cohort study. Arch Pediatradolesc Med. 2010; 164:470–477. [PubMed: 20439799]
- Canitano R. Epilepsy in autism spectrum disorders. Eur Child Adolesc Psychiatry. 2007; 16:61–66. [PubMed: 16932856]
- Heneka MT, O’Banion MK. Inflammatory processes in Alzheimer’s disease. J Neuroimmunol. 2007; 184:69–91. [PubMed: 17222916]
- Pandis D, Scarmeas N. Seizures in Alzheimer disease: clinical and epidemiological data. Epilepsy Curr. 2012; 12:184–187. [PubMed: 23118603]
- Cai H, Cong WN, Ji S, et al. Metabolic dysfunction in Alzheimer’s disease and related
neurodegenerative disorders. Curr Alzheimer Res. 2012; 9:5–17. [PubMed: 22329649] - Stafstrom CE, Rho JM. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol. 2012; 3:59. [PubMed: 22509165]
- Yau PL, Castro MG, Tagani A, et al. Obesity and metabolic syndrome and functional and structural brain impairments in adolescence. Pediatrics. 2012; 130:e856–864. [PubMed: 22945407]
У меня ревматоидный артрит, 7 лет. На кето боль уменьшается, я стала обходиться почти без НПВС. Но при строгом соблюдении диеты, желательно без всяких вкусняшек, которые разрешены и без срывов. Также у меня нет в рационе молочки и орехов. Соблюдаю ИГ
Кето должно помогать людям с РА. Следите также за уровнем витамина Д. В этом блоге есть история Микейлы Петерсон, у которой псориатический артрит. Ей пришлось перейти даже на карнивор — питание одним мясом травоядных.
Спасибо! Кстати, я тоже ввела витамин Д и сразу почувствовала улучшение, но не связала эти вещи воедино.